

Responding to the Prescription Opioid and Heroin Crisis: An Epidemic of Addiction

Andrew Kolodny, MD


Co-Director, Opioid Policy Research Collaborative Heller School for Social Policy and Management Brandeis University

Conflict of Interests


I have no relevant financial relationships to disclose.

Opium











































Unintentional Drug Overdose Deaths United States, 1970–2007






Drug Overdose Deaths by Major Drug Type, United States, 1999–2010



CDC, National Center for Health Statistics, National Vital Statistics System, CDC Wonder. Updated with 2010 mortality data.




Your Source for Credible Health Information

Overdose Deaths Involving Opioids, by Type of Opioid, United States, 2000-2016


SOURCE: CDC/NCHS, National Vital Statistics System, Mortality. CDC WONDER, Atlanta, GA: US Department of Health and Human Ser vices, CDC; 2016. https://wonder.cdc.gov/.

Heroin treatment admissions : 2003-2013




SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Treatment Episode Data Set (TEDS). Data received through 01.23.15.

Death rates from overdoses of heroin or prescription opioid pain relievers (OPRs), by age group



Age group (yrs)

SOURCE: CDC. Increases in Heroin Overdose Deaths — 28 States, 2010 to 2012 MMWR. 2014, 63:849-854



Source: J. Katz. NYT Short Answers to Hard Questions About the Opioid Crisis August 10, 2017

17

Three Opioid-Addicted Cohorts


- 20-40 y/o, disproportionately white, significant heroin use, <u>opioid addiction began with Rx use</u> (addicted after 1995)
- 40 y/o & up, disproportionately white, mostly Rx opioids, <u>opioid addiction began with Rx use</u> (addicted after 1995)
- 3. 50 y/o & up, disproportionately non-white, mostly heroin users, <u>opioid addiction began in teen years</u> with heroin use (addicted before 1995)


In one year, drug overdoses killed more Americans than the entire Vietnam War did


Dramatic Increases in Maternal Opioid Use and Neonatal Abstinence Syndrome


Children of the Opioid Epidemic Are Flooding Foster Homes. America Is Turning a Blind Eye.

How the opioid crisis decimated the American workforce










23




Incomplete data

19 - 44


< 8

8 - 14

SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Treatment Episode Data Set (TEDS). Data received through 11.03.10.



2009 (range 1 – 379)




SOURCE: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Treatment Episode Data Set (TEDS). Data received through 11.03.10.

Rates of Opioid Sales, OD Deaths, and Treatment, 1999–2010 Opioid Sales KG/10,000 Opioid Deaths/100,000 **Opioid Treatment Admissions/10,000** Rate 4

Pro-painkiller lobby shapes policy amid drug epidemic

Matthew Perrone and Ben Wieder, Associated Press and Center for Public Integrity




POLITICAL SPENDING

Opioid manufacturers and their allies have contributed roughly \$80 million to state and federal candidates and have spent about \$746 million on state and federal lobbying since 2006. How the spending breaks down:

to State to Federal for State/Federal candidates \$109 mil. \$716 mil. 45% 54% Reps


USA oxycodone consumption (mg/capita) 1980–2015



Sources: International Narcotics Control Board; World Health Organization population data

Prescription opioid volume peaked in 2011 at 240 billion milligrams of morphine equivalents and have declined by 29% to 171 billion

Chart 16: Narcotic Analgesic Dispensed Volume in Morphine Milligram Equivalents (MME) Bn




Source: IQVIA "SMART - Launch Edition", Dec 2017

Dollars Spent Marketing OxyContin (1996-2001)

Figure 1: Promotional Spending for Three Opioid Analgesics in First 6 Years of Sales

Absolute dollars in millions 30



Source: United States General Accounting Office: Dec. 2003, "OxyContin Abuse and Diversion and Efforts to Address the Problem."

Industry-funded "educational" messages

- Physicians are needlessly allowing patients to suffer because of "opiophobia."
- Opioid addiction is rare in pain patients.
- Opioids can be easily discontinued.
- Opioids are safe and effective for chronic pain.

Industry-funded organizations campaigned for greater use of opioids

- Pain Patient Groups
- Professional Societies

The Joint Commission



The Federation of State Medical Boards

"The risk of addiction is much less than 1%"

Porter J, Jick H. *Addiction rare in patients treated with narcotics*. N Engl J Med. 1980 Jan 10;302(2):123

Cited 824 times (Google Scholar)

N Engl J Med. 1980 Jan 10;302(2):123.

ADDICTION RARE IN PATIENTS TREATED WITH NARCOTICS

To the Editor: Recently, we examined our current files to determine the incidence of narcotic addiction in 39,946 hospitalized medical patients¹ who were monitored consecutively. Although there were 11,882 patients who received at least one narcotic preparation, there were only four cases of reasonably well documented addiction in patients who had no history of addiction. The addiction was considered major in only one instance. The drugs implicated were meperidine in two patients,² Percodan in one, and hydromorphone in one. We conclude that despite widespread use of narcotic drugs in hospitals, the development of addiction is rare in medical patients with no history of addiction.

> JANE PORTER HERSHEL JICK, M.D. Boston Collaborative Drug Surveillance Program Boston University Medical Center

Waltham, MA 02154

- 1. Jick H, Miettinen OS, Shapiro S, Lewis GP, Siskind Y, Slone D. Comprehensive drug surveillance. JAMA. 1970; 213:1455-60.
- 2. Miller RR, Jick H. Clinical effects of meperidine in hospitalized medical patients. J Clin Pharmacol. 1978; 18:180-8.

REVIEW

Annals of Internal Medicine

The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop

Roger Chou, MD; Judith A. Turner, PhD; Emily B. Devine, PharmD, PhD, MBA; Ryan N. Hansen, PharmD, PhD; Sean D. Sullivan, PhD; Ian Blazina, MPH; Tracy Dana, MLS; Christina Bougatsos, MPH; and Richard A. Deyo, MD, MPH

Background: Increases in prescriptions of opioid medications for chronic pain have been accompanied by increases in opioid overdoses, abuse, and other harms and uncertainty about long-term effectiveness.

Purpose: To evaluate evidence on the effectiveness and harms of long-term (>3 months) opioid therapy for chronic pain in adults.

Data Sources: MEDLINE, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, PsycINFO, and CINAHL (January 2008 through August 2014); relevant studies from a prior review; reference lists; and ClinicalTrials.gov.

Study Selection: Randomized trials and observational studies that involved adults with chronic pain who were prescribed long-term opioid therapy and that evaluated opioid therapy versus placebo, no opioid, or nonopioid therapy; different opioid dosing strategies; or risk mitigation strategies.

Data Extraction: Dual extraction and quality assessment.

Data Synthesis: No study of opioid therapy versus no opioid therapy evaluated long-term (>1 year) outcomes related to pain, function, quality of life, opioid abuse, or addiction. Good- and

fair-quality observational studies suggest that opioid therapy for chronic pain is associated with increased risk for overdose, opioid abuse, fractures, myocardial infarction, and markers of sexual dysfunction, although there are few studies for each of these outcomes; for some harms, higher doses are associated with increased risk. Evidence on the effectiveness and harms of different opioid dosing and risk mitigation strategies is limited.

Limitations: Non-English-language articles were excluded, meta-analysis could not be done, and publication bias could not be assessed. No placebo-controlled trials met inclusion criteria, evidence was lacking for many comparisons and outcomes, and observational studies were limited in their ability to address potential confounding.

Conclusion: Evidence is insufficient to determine the effectiveness of long-term opioid therapy for improving chronic pain and function. Evidence supports a dose-dependent risk for serious harms.

Primary Funding Source: Agency for Healthcare Research and Quality.

Ann Intern Med. 2015;162:276-286. doi:10.7326/M14-2559 www.annals.org For author affiliations, see end of text.

This article was published online first at www.annals.org on 13 January 2015.

JAMA | Original Investigation

Effect of a Single Dose of Oral Opioid and Nonopioid Analgesics on Acute Extremity Pain in the Emergency Department A Randomized Clinical Trial

Andrew K. Chang, MD, MS; Polly E. Bijur, PhD; David Esses, MD; Douglas P. Barnaby, MD, MS; Jesse Baer, MD

Key Points

Question Do any of 4 oral combination analgesics (3 with different opioids and 1 opioid-free) provide more effective reduction of moderate to severe acute extremity pain in the emergency department (ED)?


Findings In this randomized clinical trial of 411 ED patients with acute extremity pain (mean score, 8.7 on the 11-point numerical rating scale), there was no significant difference in pain reduction at 2 hours. Mean pain scores decreased by 4.3 with ibuprofen and acetaminophen (paracetamol); 4.4 with oxycodone and acetaminophen; 3.5 with hydrocodone and acetaminophen; and 3.9 with codeine and acetaminophen.

Meaning For adult ED patients with acute extremity pain, there were no clinically important differences in pain reduction at 2 hours with ibuprofen and acetaminophen or 3 different opioid and acetaminophen combination analgesics.

Table 2. Numerical Rating Scale (NRS) Pain Scores and Decline in Pain Scores by Treatment Group

	NRS Pain Score, Mean (95% CI) ^a				
	lbuprofen and Acetaminophen ^b	Oxycodone and Acetaminophen ^c	Hydrocodone and Acetaminophen ^d	Codeine and Acetaminophen ^e	P Value [†]
No. of patients ⁹	101	104	103	103	
Primary end point: decline in score to 2 h	4.3 (3.6 to 4.9)	4.4 (3.7 to 5.0)	3.5 (2.9 to 4.2)	3.9 (3.2 to 4.5)	.053
Baseline score	8.9 (8.5 to 9.2)	8.7 (8.3 to 9.0)	8.6 (8.3 to 9.0)	8.6 (8.2 to 8.9)	.47
Score at 1 h	5.9 (5.3 to 6.6)	5.5 (4.9 to 6.2)	6.2 (5.6 to 6.9)	5.9 (5.2 to 6.5)	.25
Score at 2 h	4.6 (3.9 to 5.3)	4.3 (3.6 to 5.0)	5.1 (4.5 to 5.8)	4.7 (4.0 to 5.4)	.13
Decline in score to 1 h	2.9 (2.4 to 3.5)	3.1 (2.6 to 3.7)	2.4 (1.8 to 3.0)	2.7 (2.1 to 3.3)	.13

One- and 3-year probabilities of continued opioid use among opioidnaïve patients, by number of days' supply* of the first opioid prescription — United States, 2006–2015




* Days' supply of the first prescription is expressed in days (1–40) in 1-day increments.

Source: Shah A, Hayes CJ, Martin BC. Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use — United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66:265–269. Controlling the epidemic: A Three-pronged Approach

- **Prevent** new cases of opioid addiction.
- Treat people who are already addicted.
- Reduce supply from pill mills and the blackmarket.


How the opioid lobby frames the problem:

Who Will Be Affected by Rescheduling?



Source: Slide presented by Dr. Lynn Webster at FDA meeting on hydrocodone upscheduling, Jan 25th, 2013.

Comparison of Mortality Data from AIDS Case Reports and Death Certificates in Which HIV Disease Was Selected as the Underlying Cause of Death, United States, 1987–2006





*For comparison with data for 1999 and later years, data in the bottom (red) line for 1987–1998 were modified to account for *ICD-10* rules instead of *ICD-9* rules.




Buprenorphine Experience in France

Introduced in the mid 90s

• 79% decline in OD deaths in 6 years

 Use of mono product (not formulated with naloxone) associated with diversion and injection use



From: Buprenorphine Use: The International Experience Clin Infect Dis. 2006;43(Supplement_4):S197-S215. doi:10.1086/508184 Clin Infect Dis | © 2006 by the Infectious Diseases Society of America

Barriers to Buprenorphine

- Ideological
- Mandatory 8-hour training
- Federally imposed patient caps
- Federally imposed ban on NP and PA prescribing (ban lifted in 2017)
- Limited integration of addiction treatment in primary care

Summary

• The U.S. is in the midst of a severe epidemic of opioid addiction

- To bring the epidemic to an end:
 - We must prevent new cases of opioid addiction
 - We must ensure access to treatment for people already addicted